Results of survival analysis indicated a significantly longer overall survival (OS) duration in patients belonging to the YTHDC2 high expression group compared to those belonging to the YTHDC2 low expression group in both TCGA-CRC and IMvigor210 cohorts (Figures 2(d) and 2(e)). This evidence concerns the gene YTHDC2 and colorectal carcinoma.